AACR 2023 | PD-L1 and alternative biomarkers in head and neck cancer

Ezra Cohen, MD, FRCPSC, FASCO, Moores Cancer Center at UC San Diego Health, San Diego, CA, provides an overview of biomarkers in head and neck cancer. Whilst PD-L1 is currently used as a predicative biomarker, high PD-L1 expression does not necessarily correspond to responses to immunotherapy. There are other biomarkers under investigation such as CD8 infiltration, tumor mutational burden (TMB), and 9p24 deletion. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.